Bio-Gene Technology Ltd. ( (AU:BGT) ) has provided an update.
Bio-Gene Technology Limited reported several key achievements for the six months ending December 2024, including a collaboration with Envu to develop Flavocide® for mosquito management, successful pilot-scale production of Flavocide, and the initiation of safety studies in Europe and India. The company also completed its thirteenth Qcide® harvest, improved seed and seedling production, and expanded formulation development programs. Additionally, Bio-Gene strengthened its intellectual property portfolio with six new patents and five new applications, positioning itself strongly in the bio-insecticide market.
More about Bio-Gene Technology Ltd.
Bio-Gene Technology Limited is an Australian company focused on developing novel bio-insecticides to tackle global challenges related to insecticide resistance and toxicity. The company’s unique products, based on naturally occurring compounds, aim to control pests effectively while minimizing impacts on human health and the environment. Bio-Gene’s products have applications in public health, crop protection, grain storage, and consumer use, addressing market demands for safe and effective pest management solutions.
YTD Price Performance: -17.50%
Average Trading Volume: 998,447
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$6.64M
For detailed information about BGT stock, go to TipRanks’ Stock Analysis page.